Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Virginia Commonwealth University, Richmond Virgina, United States

Survival: 10.0 months
Toxicity Grade: 3
Treatments: Immunotherapy
Drugs: Proleukin
Country: United States
City/State/Province: Richmond Virgina
Hospital: Virginia Commonwealth University
Journal: Link
Date: 1/2006

Patients: This phase 2 study involved 26 patients with advanced cutaneous melanoma (all with the Human Leukocyte Antigen genotype).

Treatment: Treatment consisted of immunotherapy - melanoma peptide vaccination (g209-2M) and low dose interleukin-2.

Toxicity: Toxicities included: grade 3 hypertension, arrhythmia, rash and nausea.

Results: Overall median survival was 10 months and no responses were reported. This study demonstrated that the combination of g209-2M and low-dose IL-2 is not active in melanoma. A preliminary report released subsequent to initiation of this study suggested that the combination of g209-2M and high-dose IL-2 is less effective than previously suggested.

Correspondence: Dr. John D. Roberts

E-mail to a Friend Email Physician More Information